{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth&page=32", "query": { "condition": "Growth", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 1656, "total_pages": 166, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T00:02:08.481Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00830063", "title": "Tanezumab In Osteoarthritis Of The Knee (2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis", "Osteoarthritis" ], "interventions": [ { "name": "tanezumab 10 mg", "type": "BIOLOGICAL" }, { "name": "tanezumab 5 mg", "type": "BIOLOGICAL" }, { "name": "naproxen", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 832, "start_date": "2009-05-05", "completion_date": "2010-08-31", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-10-24T00:02:08.481Z", "location_count": 94, "location_summary": "Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 72 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Anniston", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00830063" }, { "nct_id": "NCT00970502", "title": "Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer of the Pharynx", "Cancer of the Larynx", "Cancer of the Neck", "Paranasal Sinus Neoplasms", "Cancer of the Head" ], "interventions": [ { "name": "erlotinib + celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnny Kao", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2007-02", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2017-04-10", "last_synced_at": "2026-10-24T00:02:08.481Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00970502" }, { "nct_id": "NCT02261961", "title": "Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sarcopenia", "Aging", "Immune Function" ], "interventions": [ { "name": "TDAP", "type": "BIOLOGICAL" }, { "name": "Acute Resistance Exercise", "type": "OTHER" }, { "name": "Resistance Exercise Training", "type": "OTHER" }, { "name": "Post-training Follow-up", "type": "OTHER" }, { "name": "Nutritional Supplement (Muscle Armor)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo (Kool-Aid)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DIETARY_SUPPLEMENT" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "60 Years to 80 Years" }, "enrollment_count": 59, "start_date": "2014-07-23", "completion_date": "2019-09-30", "has_results": true, "last_update_posted_date": "2021-09-28", "last_synced_at": "2026-10-24T00:02:08.481Z", "location_count": 1, "location_summary": "North Little Rock, Arkansas", "locations": [ { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02261961" }, { "nct_id": "NCT05400122", "title": "Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Hematologic Malignancy", "Rectum Cancer", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Myeloproliferative Syndrome", "Plasma Cell Myeloma", "Gastric Cancer", "Esophageal Cancer", "Esophagus Cancer", "Gastric Cancer, Metastatic", "Unresectable Esophageal Cancer", "Metastatic Esophageal Cancer" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Natural Killer Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Wald", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-09-09", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-24T00:02:08.481Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05400122" }, { "nct_id": "NCT04952753", "title": "Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "NIS793", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 204, "start_date": "2021-11-15", "completion_date": "2025-01-20", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-10-24T00:02:08.481Z", "location_count": 7, "location_summary": "Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04952753" }, { "nct_id": "NCT03884322", "title": "Self Regulated Physical Activity and Bone Growth Enhancement in Premature Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prematurity", "VLBW - Very Low Birth Weight Infant" ], "interventions": [ { "name": "Prepod", "type": "OTHER" }, { "name": "Joint compression exercises", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Asante Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "32 Weeks", "maximum_age": "36 Weeks", "sex": "ALL", "summary": "32 Weeks to 36 Weeks" }, "enrollment_count": 54, "start_date": "2013-10-21", "completion_date": "2018-03-30", "has_results": false, "last_update_posted_date": "2019-03-21", "last_synced_at": "2026-10-24T00:02:08.481Z", "location_count": 1, "location_summary": "Medford, Oregon", "locations": [ { "city": "Medford", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03884322" }, { "nct_id": "NCT00570375", "title": "The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2007-11", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-10-24T00:02:08.481Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00570375" }, { "nct_id": "NCT05416333", "title": "Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Central Centrifugal Cicatricial Alopecia" ], "interventions": [ { "name": "azelaic acid", "type": "DRUG" }, { "name": "usual medication for CCCA", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2024-08-12", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-24T00:02:08.481Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05416333" }, { "nct_id": "NCT04895358", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "liposomal doxorubicin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "normal saline", "type": "DRUG" }, { "name": "dextrose", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 342, "start_date": "2021-06-18", "completion_date": "2027-12-18", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-24T00:02:08.481Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Monterey", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895358" }, { "nct_id": "NCT03797326", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Triple Negative Breast Cancer", "Ovarian Cancer", "Gastric Cancer", "Colorectal Cancer", "Glioblastoma", "Biliary Tract Cancers", "Pancreatic Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 611, "start_date": "2019-02-12", "completion_date": "2024-10-28", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-24T00:02:08.481Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03797326" } ] }